OUR PRODUCT

Allterum’s Antibody

Allterum is building a franchise addressing the IL-7R pathway starting with 4A10, a monoclonal antibody targeted against CD127. CD127 is part of a receptor complex located on T-cells and Pre B-cells. Especially in the context of cancer cells, CD127 plays a critical role in driving cancer growth, being frequently expressed at a higher level, or in a more activated form, and has been posited as playing a key role in ALL oncogenesis and chemotherapy-resistance. Allterum’s 4A10 antibody is the first immunotherapy approach to target CD127. 4A10 uses the patient’s own immune system to target cancer cells for destruction. 4A10 is currently in development for the treatment of relapsed leukemia and will expand to other heme malignancies and solid tumors.
CONTACT US
Image

4A10 and CD127 (also known as IL-7Rα) in Scientific Literature

Review highlighting oncogenic mutations in the IL-7 pathway

Mutations that collaborate with IL-7Ra signaling pathways to drive ALL. Advances in Biological Regulation (2021)

READ MORE

4A10 Preclinical Data by Dr. Scott Durum’s Group

New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia (2020)

READ MORE

IL-7R is highlighted for its potential oncogenic effects in T-cell ALL

IL-7Rα is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia. Blood (2019)

READ MORE

IL-7R signaling can drive leukemia development, acceleration, and resistance to chemotherapy

IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update Adv Biol Regul (2019)

READ MORE

Targeting IL-7R with an antibody-drug conjugate is efficacious in models of T-cell ALL

A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia. Leukemia (2020)

READ MORE

IL-7R may play a key role in driving Ph-like and Ph+ B-cell acute lymphoblastic leukemia

Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Nature Communications (2020)

READ MORE

Glucocorticoid resistance is reversible with targeted inhibition of the IL-7 pathway

Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest (2020)

READ MORE

CD127 is a promising target for the treatment of pediatric acute lymphoblastic leukemia

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. Blood (2016)

READ MORE

ALLTERUM THERAPEUTICS

Advancing an innovative solution for a critical and unmet medical need

CONTACT US